Purple Biotech Ltd PPBT.OQ, PPBT.O is expected to show no change in quarterly revenue when it reports results on March 3 (estimated) for the period ending June 30 2024
LSEG's mean analyst estimate for Purple Biotech Ltd is for a loss of $1.80 per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Purple Biotech Ltd is $33.00, above its last closing price of $2.85.
This summary was machine generated February 28 at 13:33 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)